MindMap Gallery GSK Marketing Mix Analysis

GSK Marketing Mix Analysis

This analysis explores GSK’s marketing mix strategy in prescription drugs, focusing on growing market share and improving patient outcomes. Context and objectives: business goals – grow market share (vaccines, respiratory, oncology, HIV), improve patient outcomes (efficacy, safety, quality of life), navigate complex pharmaceutical landscape (regulatory, payer, provider). Product: core value proposition – innovative medicines (vaccines: Shingrix, Arexvy; respiratory: Trelegy, Nucala; oncology: Zejula, momelotinib; HIV: ViiV Healthcare). Brand architecture: portfolio brands, individual product brands. Evidence strategy: RCTs (phase 3, superiority), real-world evidence, pharmacoeconomic models (cost-effectiveness, budget impact). Pricing strategies: value-based pricing (tied to outcomes, cost-effectiveness), patient affordability initiatives (co-pay assistance, patient assistance programs, free drug), payer negotiations (formulary placement, prior authorization, step therapy), volume discounts (GPOs, health systems), outcomes-based contracts (rebates if outcomes not met). Distribution strategy: channel access – specialty pharmacy (oncology, rare disease, HIV), retail pharmacy (respiratory, vaccines), hospital (inpatient, infusion). Provider integration: electronic health records, e-prescribing, patient support hub. Specialty distribution models: limited distribution drugs, cold chain (vaccines), home delivery. GSK navigates prescription marketing through clinical differentiation, patient support, value-based pricing, and multi-channel distribution.

Edited at 2026-03-25 15:01:39
PlotWizard
PlotWizard

GSK Marketing Mix Analysis

PlotWizard
PlotWizard
  • Recommended to you
  • Outline